Good morning and welcome to a balmy February morning here in Minnesota. I am Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations, and I am pleased that you are joining us for Medtronic’s Fiscal Year 2022 Third Quarter Earnings Video Webcast. Before we start the prepared remarks, I will share a few details about today’s webcast.

Joining me are Geoff Martha, Medtronic Chairman and Chief Executive Officer and Karen Parkhill, Medtronic Chief Financial Officer. Geoff and Karen will provide comments on the results of our third quarter, which ended on January 28, 2022 and our outlook for the remainder of the fiscal year.

After our prepared remarks, our portfolio executive VPs will join us and will take questions from the sell-side analysts that cover the company. Today’s event should last about an hour. Earlier this morning, we issued a press release containing our financial statements and divisional and geographic revenue summaries.

We also posted an earnings presentation that provides additional details on our performance. The presentation can be accessed in our earnings press release or on our website at investorrelations.medtronic.com.

During today’s webcast, many of the statements we make maybe considered forward-looking statements and actual results may differ materially from those projected in any forward-looking statement.

Additional information concerning factors that could cause actual results to differ is contained in our periodic reports and other filings that we make with the SEC and we do not undertake to update any forward-looking statement.

Unless we say otherwise, all comparisons are on a year-over-year basis and revenue comparisons are made on an organic basis.

Third quarter organic revenue comparisons adjust only for foreign currency as there were no acquisitions or divestitures made in the last four quarters that had a significant impact on total company or individual segment quarterly revenue growth.

References to sequential revenue changes compare to the second quarter of fiscal ‘22 and are made on an as-reported basis. And all references to share gains or losses refer to revenue share in the fourth calendar quarter of 2021 compare to the fourth calendar quarter of 2020 unless otherwise stated.

Reconciliations of all non-GAAP financial measures can be found in our earnings press release or on our website at investorrelations.medtronic.com. And finally, our EPS guidance does not include any charges or gains that would be reported as non-GAAP adjustments to earnings during the fiscal year.

And with that, let’s head into the warm studio and get started..

Hello, everyone and thank you for joining us today. This morning, we reported Q3 results, delivering solid earnings growth in a challenging market. We felt the short-term impacts of Omicron in January, particularly in the U.S., causing our Q3 revenue to fall short of our expectations.

The COVID resurgence affected not only procedure volumes, but also created acute periods of worker absenteeism with our customers, suppliers and in our own operations and field teams. Now that said, COVID infections in the U.S. are declining. Available hospital ICU capacity is increasing and procedure volumes are picking up.

While some of the impacts from the pandemic, like inflation, supply chain issues and healthcare worker shortages will linger, we do expect that our markets, our customers and our industry are on the path to recovery.

Over the last 18 months, we have made significant changes to our operating model, moving to 20 focused operating units as well as making major enhancements to our culture and incentives. These changes have improved our pace of innovation and our competitiveness, as evidenced by recent product filings and approvals that came faster than expected.

And we are not finished driving change. We are accelerating improvements to our global supply chain and operations, leveraging our scale to further improve quality, increase product availability and reduce cost. In addition, we have enhanced our portfolio management and capital allocation processes.

Our new operating model is giving us line of sight into what is required to compete and win over the long-term in each of our businesses. As a result, we are looking at our portfolio with a more critical eye, with a focus on growth and creating shareholder value.

I’d be surprised if there weren’t changes over the coming fiscal year, but I don’t know yet if they will be smaller or more significant. Now, let’s look at our third quarter results, starting with our market share performance.

Now, market share is an important metric and a reflection of the culture and incentive changes that we are making in the company. About 60% of our businesses held or won share in the last calendar quarter.

While that’s down slightly from last quarter due to some supply constraints and where certain businesses are in their product cycles, it is a significant improvement from where Medtronic was just 18 months ago.

So, starting with our Cardiovascular Portfolio, in Cardiac Rhythm Management, one of our largest businesses, we continue to build on our category leadership, adding over 1.5 points of share.

We are winning share in both high and low power devices and we recently launched our Micra AV Leadless Pacemaker in Japan and Micra VR in China, resulting in international Micra growth of over 50% in Q3. In Peripheral Vascular Health, we won about 1 point of share with strong growth in our Abre deep venous stents and venous seal closure system.

And in Cardiac Surgery, we gained over 1 point of share on the strength of our extracorporeal life support products. In our Medical Surgical portfolio, we estimate we gained share in GI, driven by momentum from the recently launched Emprint HP Generator and our Beacon endoscopic ultrasound franchise.

In Respiratory Interventions, despite the year-over-year headwind as ventilator sales continue to return to pre-pandemic levels, we estimate we gained about 400 basis points of share.

We won share in premium ventilation with our Puritan Bennett 980, in video laryngoscopes with our McGrath-Mac and in core airways with our TaperGuard endotracheal tubes. In our Neuroscience portfolio, we increased our market share in Cranial & Spinal Technologies.

We are launching new spine implants that enhance the overall value of our ecosystem of preoperative planning software, imaging, navigation and robotic systems as well as powered surgical instruments, all of which are transforming care in spine surgery.

In Neuromodulation, we have great momentum from new products in both pain stim and brain modulation. In pain stim, despite the headwinds from Omicron, we estimate we gained over 1 point of share, driven by both our Intellis with DTM technology and Vanta recharge-free systems.

And in brain modulation, while we continue to face headwinds from replacement devices, our business grew 15% on strong adoption of our Percept neurostimulator with BrainSense technology, paired with our SenSight directional lead.

Medtronic is the only company with sensing capabilities in our deep brain stimulators, which drove about 10 points of new implant share and over 1 point of overall DBS share in Q3 and we expect this momentum to continue.

Another business with momentum is our Neurovascular business, where we are back to winning share, picking up about 2 points this quarter. We are seeing strength from our pipeline family of flow diverters for treating intracranial aneurysms.

Our flow diversion launches in Japan, CE Mark countries and the United States, coupled with broader portfolio growth in China, propelled Neurovascular to 12% growth this quarter. Now, while the majority of our businesses are winning share, we have some businesses that lost share in Q3, where we are focused on improving our performance.

In Cardiac Diagnostics, despite year-over-year share loss, we gained share sequentially for the first time in many quarters.

We have made good progress increasing our manufacturing capacity for our LINQ II insertable cardiac monitor and we began our rollout of our AccuRythm artificial intelligence algorithms, which were just enabled for all LINQ II patients in the U.S.

We expect ongoing supply improvement and additional AI detection algorithms, along with new indications to expand the market and drive growth. In our Structural Heart & Aortic business, we lost share in aortic due to supply constraints and continued pressure from our Valiant Navion recall and competitive launches.

At the same time though, we maintained our TAVR share in Q3, growing in the mid-teens. In our Surgical Innovations business, we lost a little over 0.5 point of share overall due to acute resin shortage that impacted our flagship LigaSure vessel sealing portfolio.

This was partially offset by increased share in advanced stapling given strong market adoption of our Tri-Staple Reinforced Reloads as well as share gains in hernia and sutures. The good news here is that our teams have improved our resin supply and we expect to be able to meet demand in Q4.

In Patient Monitoring, we estimate we lost a few points of share due to a difficult comparison from the strength we had last year in pulse oximetry and capnography monitor sales. However, our share has been relatively consistent for the past four quarters. In Pelvic Health, procedures slowed this past quarter and we lost some share.

We expect this market to recover and we are well-positioned to compete. In ENT, we lost share for the first time in a long time, given some temporary supply chain disruptions that we expect to have resolved going forward. And in Diabetes, we continue to lose share, predominantly in the U.S.

Look, we are extremely focused on resolving our warning letter and bringing new products to the U.S. market although timing is difficult to predict. In December, CMS expanded coverage for our CGM sensors, including those integrated with insulin pumps and we are pleased that this will take effect for Medicare patients at the end of this month.

In the international markets, we launched the 770G in Japan last month, making it the first hybrid closed loop system available in that country. And in Europe, we continue to see success and strong adoption of our 780G with the Guardian 4 sensor. Next, let’s turn to our product pipeline.

We have launched over 200 products in the U.S., Western Europe, Japan and China in the last 12 months and these are having an impact across our businesses. At the same time, we continue to advance new technologies that are in development with increased investments in R&D.

We are expecting these investments to create new markets, disrupt existing ones and accelerate the growth profile of Medtronic. Now, starting with our Cardiovascular portfolio, we continue to make progress in Cardiac Rhythm Management on disrupting the ICD market with our Aurora extravascular ICD. Our U.S. pivotal study is fully enrolled.

We continue to expect CE Mark approval later this calendar year and U.S. approval next calendar year. Our EV ICD can both pace and shock without any leads inside the heart and veins. And it does this in a single device that is the same size as a traditional ICD.

We believe Aurora will accelerate adoption of EV ICDs and make this a $1 billion market by 2030. In Cardiac Ablation Solutions, we are advancing a number of technologies to become a leader in the $8 billion EP ablation market.

We are rolling out our DiamondTempt RF ablation system as well as our exclusive first line paroxysmal AF treatment indication using our cryoablation system. We also continue to make progress with our anatomical PulseSelect PFA system, which has breakthrough device designation from the FDA.

Our global pivotal trial completed enrollment back in November and we are very excited about how our PFA system could disrupt the EP ablation market. Last month, we announced our intent to acquire Affera.

Affera has several development programs underway, including a differentiated mapping and navigation system that closes a competitive gap in our product portfolio and a focal PFA system that is a separate and complementary platform to our anatomical PFA system. We are looking forward to welcoming the Affera team into Medtronic.

Moving to our Symplicity renal denervation procedure for hypertension, we continue to enroll our ON MED study and expect to complete the 6-month follow-up in the second half of this calendar year. We will then submit the data to the FDA as ON MED is the final piece of our submission to seek approval for Symplicity.

Adding to our body of evidence, 3-year data from our ON MED pilot study will be presented at the ACC scientific sessions in April. In Structural Heart, we now expect to begin the limited U.S. market release of our Evolut FX valve in Q1, followed by full market release later in fiscal ‘23.

Evolut FX enhances ease-of-use improvements in deliverability, implant visibility and deployment stability. In China, we expect to launch our Evolut PRO valve this quarter, our first entry into this large and underpenetrated TAVR market. We also continue to advance our transcatheter mitral and tricuspid development programs.

In our APOLLO pivotal trial for TMVR, we just had the first implant using our transfemoral delivery system and we expect this new system to meaningfully accelerate patient enrollment.

Moving to our Medical Surgical portfolio and our surgical robotics program, we have made progress improving our supply chain and manufacturing and remain focused on scaling production.

At the same time, we continue to add regulatory approvals and expand our limited market release, most recently in Canada, Australia and Israel and we intend to start our U.S. urology clinical trial soon.

In addition to uro and GYN cases, surgeons in Panama, Chile and India are now performing general surgery procedures, with Hugo, including advanced cases like colorectal and lower anterior resection surgeries. And we announced earlier this month the first Hugo procedures in Europe.

In Diabetes, our MiniMed 780G insulin pump, combined with our Guardian 4 sensor, continue to be under active review with the FDA, with approval subject to our warning letter. When approved and launched in the U.S., we expect this system to be highly differentiated and accelerate growth in our diabetes business.

We continue to expect submission of our next generation sensor Simplera to the FDA this quarter. Simplera is fully disposable, easy to apply and half the size of Guardian 4. Finally, we are making progress on multiple next-gen sensor and pump programs, including patch pumps, although we haven’t disclosed details for competitive reasons.

While it will take time, we expect the technology pipeline investments we are making will result in our diabetes business being accretive to total company growth and eventually grow with this important market.

Now, turning to our Neuroscience portfolio, we were pleased to receive FDA approval for our diabetic peripheral neuropathy indication for our Intellis and Vanta spinal cord stimulators last month. This came following the FDA’s rigorous review of our clinical submission and years earlier than we had previously communicated.

The approval represents the beginning of a multiyear market development process, which we are uniquely suited to execute given our presence in both the pain stim and the diabetes markets.

We believe that DPN market opportunity will reach $300 million by FY ‘26 and with an annual TAM of up to $1.8 billion, making DPN for SCS one of the biggest market opportunities in med tech.

In addition to DPN, we also continue to make progress on expanding indications for SCS and to non-surgical refractory back pain and upper limb and neck chronic pain. If that was not enough for pain stim, we are also excited about our inceptive ECAP’s closed loop spinal cord stimulator, which we submitted to the FDA late last year.

We expect inceptive’s closed-loop therapy that optimizes pain relief for patients to revolutionize the SCS market. Finally, in Pelvic Health, we are expecting FDA approval for our next-gen InterStim recharge-free device in the first half of this calendar year.

With its designed best-in-class battery, constant current and full-body MRI compatibility at both 1.5 and 3 Tesla, we expect this device will extend our category leadership in sacral neuromodulation. And with that, I will turn it over to Karen to discuss our financial performance and our guidance.

Karen?.

Thank you, Geoff. Our third quarter organic revenue increased 2%. While we were tracking to our quarterly guidance in early January, the impacts from this latest wave of COVID affected our revenue in the last month of the quarter.

Despite the challenging revenue, we controlled expenses and delivered adjusted EPS in line with our guidance and $0.01 ahead of consensus. From a geographic perspective, our U.S. revenue was flat, and non-U.S. developed markets grew 1%, given the impacts of Omicron.

Our emerging markets were relatively stronger, growing 7%, with strength in South Asia, Latin America and the Middle East and Africa. Converting our earnings into strong free cash flow is a priority. Our year-to-date free cash flow was $4.3 billion, up 23% from last year and we continue to target a full year conversion of 80% or greater.

And we remain focused on allocating our capital to generate strong future growth and shareholder returns. We are increasing our organic R&D investments broadly across the company to fuel the pipeline that Geoff walked through earlier and we are supplementing this with attractive tuck-in acquisitions.

Since the beginning of last fiscal year, we have announced 8 acquisitions totaling over $3.2 billion in total consideration, including last month’s acquisition of Affera in our Cardiac Ablation business. At the same time, we are increasing our minority investments in companies that could become future acquisitions as was the case with Affera.

We have a commitment to return more than 50% of our free cash flow to our shareholders, primarily through our attractive and growing dividend. We are an S&P dividend aristocrat. And fiscal year-to-date, we paid over $2.5 billion in dividends to our shareholders.

And finally, particularly in periods where we see share price dislocation, we look to execute opportunistic share repurchases as was the case this quarter. Fiscal year-to-date, we have repurchased over $1.1 billion of our stock.

Turning to guidance, while procedure volumes are still impacted from Omicron in the first few weeks of February, we are beginning to see improvement. Our outlook assumes continued procedure volume recovery through March and April. And we expect to be back to pre-COVID levels in most of our markets before the end of the fourth quarter.

Assuming that holds, for the fourth quarter, we are comfortable with current Street consensus for our organic revenue growth of approximately 5.5%. At recent foreign exchange rates, currency would be a headwind on fourth quarter revenue of approximately $185 million.

By segment, we would model Cardiovascular at 7% to 8% growth, Neuroscience at 2.5% to 3.5% growth, Medical Surgical at 7.5% to 8.5% growth, and Diabetes down 6% to 7%, all on an organic basis. On the bottom line, we expect fourth quarter non-GAAP diluted EPS in the range of $1.56 to $1.58, in line with current consensus.

And at recent rates, we expect currency to have a flat to slightly positive impact on the bottom line. Before I send it back to Geoff, I want to acknowledge the additional strain that the recent COVID resurgence has placed on our customers and our employees over the past couple of months.

I am truly grateful for the perseverance that both healthcare workers and our employees have demonstrated to ensure patients receive our life-changing therapies around the world. Back to you, Geoff..

alleviating pain, restoring health and extending life for millions of people around the world. Now, let’s move to Q&A. We are going to try to get to as many as analysts as possible. So we ask that you limit yourself to just one question and only if needed, a related follow-up.

If you have additional questions, you can reach to Ryan and the Investor Relations team after the call.

With that, Win, can you please give the instructions for asking a question?.

[Operator Instructions] For today’s session, Geoff, Karen and Ryan are joined by Sean Salmon, EVP and President of the Cardiovascular Portfolio and the Diabetes operating unit; Bob White, EVP and President of the Medical Surgical portfolio; and Brett Wall, EVP and President of the Neuroscience Portfolio.

We will pause for a few seconds to assemble the queue. We will take the first question from Robbie Marcus at JPMorgan. Robbie, go ahead..

Great. Thanks a lot and congrats on the quarter. Maybe my first question, I think one of the bigger investor questions, that’s building here, especially with some of the warning letter and the delays in Diabetes and some of the inflation pressure we’re seeing with some of your competitors.

Any early thoughts on how we should be thinking about fiscal ‘23? There is a wide range on estimates. So I just wanted to get any early sense you had for us? Thanks..

Sure. Maybe I’ll – first of all, thanks for the question. I agree it’s a big question, and maybe I’ll turn this over to Karen to provide some color commentary on FY ‘23..

Thank you, Geoff and Robbie. So I would first say it’s early. And obviously, we’re going to give our full year outlook on our Q4 call in May. And we’re working through our planning process as we speak. And we’ve noted before with you that there are more puts and takes than normal for next fiscal year. So let me help by sharing some broad thoughts.

On revenue, we continue to drive to our long-term organic revenue growth goal of 5% plus, for sure. Although I would say on the plus side, the plus side of that, LRP may be more difficult in FY ‘23, just given some of the challenges that we’ve talked about.

We are, as you know, expecting really great product launches, Geoff talked about several of them on the call. And we do expect a continued rebound in procedure volumes in our markets. And as we think about FX on the top line for next year, think about that as being a few hundred million dollar headwind at recent rates.

On the bottom line, you’ve heard from others around the increased pressure from the macro environment. And we’ve got that same increased pressure on things like inflation and wage adjustments. And we’ve noted last month that currency is expected to flip from a tailwind to a headwind next fiscal year.

And we’ve also shared that we’ve got some dilution from our Affera acquisition. Those last two combined could impact EPS by a few hundred basis points. While we continue to work to offset these headwinds, we certainly don’t want to shortchange our investments and our meaningful growth drivers for the future.

And it’s those investments that are really going to help us deliver on that plus side of the 5% plus over the long-range plan. So I would say FY ‘23 will be a unique and challenging year just given the macro environment and the timing of our major pipeline launches. And on the bottom line, we do expect to grow EPS next year, certainly.

But at this stage, we don’t expect it to be above revenue growth. I want to make sure, though, that you take away from this that we are still very committed to our long-range plan. We’ve got investments in quality along with the more-than-modest FX dilution next fiscal year that should subside going forward.

And while it’s hard to predict the macro factors like inflation and wage adjustments, I’m not sure they’ll continue at the pace that we’re currently experiencing. And obviously, as we look forward, we expect to have meaningful revenue growth to go along with those investments that we’re prioritizing, which will ultimately help drive EPS growth.

So I hope that color is helpful, Robbie..

Yes, that’s great. And then as my follow-up, Geoff, at the JPMorgan conference, you first mentioned may be doing some bigger changes to the business. You mentioned it again today. I was just hoping you could give us a little flavor for what you’re thinking.

Is it divestitures? Is it a bigger breakup of the company? And what’s the time frame we should be thinking about for some of the larger potential actions? Thanks..

Sure, Robbie. Yes, so we’re definitely looking at the portfolio more intently. I can’t – however, at this point, I can’t really get into specifics. I will say we’re looking to improve our [indiscernible] where we are looking to improve the consistency of our growth, our North Star – to summarize it, our North Star is durable growth.

And we’re looking at our businesses and we’re evaluating them for, one, how well they fit into the portfolio, how well they fit into our strategy, are we the right owners of these assets? And then how we, Medtronic, add value and grow these businesses? It’s still at this point, like I said at the conference, we don’t know if these changes will be significant or more limited.

But I can assure you, we’re deeply, deeply committed to doing the right things for shareholders and on all of the Medtronic stakeholders. So we intend to get through this analysis and I think have more over the next several – over the course of the next fiscal year is what we said at the JPMorgan.

I don’t have any more update from that in terms of timing..

Alright. Thanks a lot. Appreciate it..

Thank you, Robbie. Next question, please, Win..

Next question comes from Vijay Kumar at Evercore ISI. Go ahead..

Vijay, are you there? Do you want to go to the next question and then come back to Vijay?.

Sorry about that. Hi, Geoff, Karen. Good morning and thanks for taking my question. There is I guess maybe one – my first one is on the guidance comments you made which was helpful.

What is the fiscal ‘23 assuming on Diabetes? Did you guys have a second meeting with the FDA? Is the warning letter going to be delinked with the approval? Or how are you treating Diabetes in that comment of 5 plus with plus being difficult.

Is that still assuming a 50 to 100 basis points headwind from Diabetes?.

On the very last part of the question, I’ll let Karen and maybe Sean chime in. In terms of – look, the dialogue with the FDA is ongoing. I mean we’ve got an ongoing dialogue on the 780G approval. We’ve got an ongoing dialogue on the warning letter.

Our priority is – they are both priorities, but our first priority is to work the warning letter issues, and we’ve been working on these, like as we talked about, for 2 years now, even before the warning letter was issued. So the dialogue with – like I said, with the FDA is ongoing, and it’s very constructive, I would say.

Karen, do you want to talk about the last part of the question there?.

Sure, Vijay. Good morning. It’s still too early to get specific. We’re in our planning process. And as we talked about before, there are a variety of outcomes and ranges that can happen, depending on the approval.

We’re obviously focused on getting that approval out as quickly as possible, and we will be working towards that, but too early to get specific on guidance. We will give that guidance, including for our business units, in the fourth quarter call..

Understood. And maybe, Geoff, my second question on the robot. Some early feedback seems to be positive. Have – you did mention supply chain has been resolved or you’re ramping up production. Maybe some sense for where production is or some color on how many surgeons have been trained. What is the order book looking like for the robot would be helpful..

Yes. Maybe I’ll bring in Bob here in a second to provide some of that – more color on that. On just overall, we’re making progress on the robot. Demand continues to be strong. We continue to get additional regulatory approvals, a couple more last quarter.

We did our first surgery in Europe and are getting good feedback from surgeons there, which I think is a great sign. And the breadth of our procedures continues to grow, get more complex.

And so we’re feeling good about the – kind of where the robot is, like that we’ve got something really powerful in our hands here and we’re going to achieve our long-term objectives here. And as we’ve said before, we anticipate a strong ramp in FY ‘23. But I’ll give Bob.

Bob, do you want to add some color here?.

Yes. Thanks, Geoff. And Vijay, thanks for the question. It was nice to read your report after the time you spent with Professor Motree as well. And certainly, what we’ve seen, Vijay, is we’ve seen some nice progress. We’re installing more systems across the world. As you know, now that we have our CE Mark approval.

As Geoff mentioned, some of the general surgery procedures taking place. And we certainly expect to continue to expand the regulatory approvals in more countries. We certainly look to expand in the future to thoracic, colorectal, hernia, bariatric procedures.

Obviously, Hugo was designed with all those procedures in mind, working with all those regulatory agencies. And the feedback itself has been really positive, Vijay. The open council has been excellent, the visualization, staying connected with the OR staff and we like about that.

We really think the council and our whole system design for where healthcare is moving, which is a real kind of cross-functional team-based approach to physician to care delivery. So obviously, as you know, you picked up some of this feedback. The way our system is designed, it’s also allowing to train multiple surgeons in parallel.

And sort of your question, we’re training lots of surgeons. We have training centers now opened up in geographies across the world and seeing really good traction there as well. So we’re going to do what we told you consistently throughout, which is expand our limited market release into these markets and continue to make progress.

But thanks for the question, and thanks for spending time with Professor Motree..

Thanks, guys..

Thank you, Vijay..

Thanks, Vijay. Next question, please, Win..

The next question comes from Pito Chickering at Deutsche Bank..

Good morning, guys. Thanks for taking my questions. On the guidance question, I understand that the macro environment for 2023 is pretty challenging.

But as you look at both labor and material inflation, do you think that, that would change your long-term EPS target? Or do you need more revenue growth to offset these margin pressures? Or do you think they can pass some of those costs all into your customers over time?.

Let me take a stab at that. First, there are things that we’re doing. I’ll let Karen talk about some of this in a second here. But we are, in addition to; we are obviously facing these inflationary pressures.

And even before the inflation kicked in, as part of our organizational kind of new operating model, one of the areas we’ve talked a lot about, move into the 20 operating units and putting more into R&D and really speeding up the pace of innovation, and I think that is working.

We’re getting good evidence around that this is working in terms of the pace of our product launches and some of these product launches coming much faster than we anticipated, like we talked about – and I talked about in the commentary like in our Pain Stim market with DPN, diabetic peripheral neuropathy approval or – and I can go off a couple of other lists, our ECAP submission for pain.

These are areas that we just spend things up. So I feel good about that. But another area that we had planned to address and now are accelerating is the operations area. And there is an opportunity there to get some more benefits of scale that we have and simplify our global operations.

And in simplifying that, that’s going to – we’re going to also invest in some enhanced capabilities there. That is going to give us a lower cost to serve, if you will, and set us up for cost of goods sold improvements over time. So that is going to help address some of this.

You also mentioned price – and again those plans were put in motion before the inflation, but we’ve been accelerating it since the inflation has hit. And then price. I mean, price, there are – we are looking more acutely at our new technology.

We have a lot of new products coming out, and we are looking at the pricing of that in the wake of some of the – of this inflation. And there are select markets around the world where I think we have the ability – we have the opportunity to improve our pricing. So we are looking at pricing as well.

So both those levers, reducing our cost to serve and setting ourselves up for cost of goods – better cost of goods sold over time and then the pricing that I just mentioned.

Karen, do you want to add?.

Yes, I’ll just add a little bit. While it varies by geography, we are seeing wage inflation in our direct labor currently of almost 9%. So that is much higher than typical. And that’s just a near-term headwind that we’re dealing with. That will impact us a bit in FY ‘23.

And on materials right now, we’re typically able to drive net material savings through productivity efficiencies and cost down initiatives. And right now, we’re expecting a couple of hundred basis points of inflation on that just in the near-term.

But again, over the long-term, we’re focused on driving revenue growth, on driving continued cost down and expense efficiencies, pricing opportunities where we have them. So we’re focused on and remain committed to that long-range plan..

Thank you so much..

Thanks, Pito. Next question, Win..

The next question comes from Matt Miksic at Credit Suisse..

Hi, thanks so much.

Can you hear me okay?.

Yes, we can hear you, Matt..

Great. So one quick one on sort of your portfolio comments. And then just a clarification on the ‘23 guidance comments, if I could. So Geoff, I think sometimes when folks ask about portfolio changes or puts and takes to your businesses, they are thinking of, just to put it bluntly, commitment to Diabetes, frankly.

So I’d love to get your thoughts on your commitment to that business now what it is in the portfolio, where you stand in terms of the process of getting it back at speed. And then I have just one clarification, as I mentioned, for Karen..

Sure. On the comments we made about the portfolio, let me start by saying it wasn’t intended to be focused on Diabetes. It’s a real, I guess, deep dive, I would say, on the whole portfolio, okay, and more intent than we’ve done in the past. Regarding Diabetes, look, I’d say we are confident in our turnaround story here.

I know the warning letter didn’t help. But we are confident in the turnaround story. We believe we have a solid pipeline of new technologies and some near-term growth opportunities.

Our clear priority though is resolving the FDA warning letter and getting these new products to market, especially in the U.S., right? In a situation when we see the products working in other markets, we know it’ll have a huge impact on patients here in the U.S. as well.

And we have multiple shots on goal to deliver competitive pump and CGM technology, through our organic R&D, through the Blackstone partnership and through some structured investments. And as we mentioned in the JPMorgan conference, we do have some parts of the pipeline that we haven’t provided much detail on for competitive reasons.

So we feel we’re further along in Diabetes in terms of not having the warning letter, but it doesn’t change the narrative in our mind. We have the technology, we have the pipeline. It’s a high-growth market, and we feel good about it..

That’s great. Thank you. And then just on – Karen, I appreciate the color on ‘23 and I understand it’s – we’re a quarter away here from formal ‘23 guidance.

But the few hundred basis point impact on EPS, you mentioned from FX and some other items, dilution from Affera, just to put a finer point on it, that’s inclusive of the Diabetes impact And also just to make sure we have the math right, that’s somewhere in the range of $0.15, $0.15 to $0.20 or something like that of a headwind from those items? Thanks..

Yes. Matt, thank you. Those items – the few hundred basis points that I talked about are just from the foreign exchange flipping from a tailwind this fiscal year to a headwind next year and from the dilution. So, it is – so you can see the magnitude just from those to temporal items.

And that foreign exchange flip, I think at least at current rates, we would say, is much more than modest. And so that’s why we point them out..

Great. Thanks..

Thanks Matt. Next question please, Win..

Next question comes from Larry Biegelsen at Wells Fargo. Go ahead Larry..

Good morning. Thanks for taking the question. So, just one on the recovery and related one on China. It looks like January was soft given your comments at JPMorgan and the results today. So, what – a little bit more color on what you have seen in February and the confidence in the Q4 guidance.

It does imply a pretty significant increase, I think sequentially. And just lastly, on China, it was flat in Q3 versus growing high teens in the second quarter. Any color on that and how you guys are thinking about VBP there? Thanks for taking the question..

Sure. Larry, on the first part of the question, yes, omicron impacted cases and it caused a broad-based absenteeism, right. And we use the word absenteeism to separate it from healthcare worker shortage.

And the healthcare worker shortage, I think is more – is going to last longer into FY ‘23 versus the absenteeism, and that’s driven by all the things you have heard about like burn out, people leaving the workforce, versus absenteeism was more short-term and acute caused by just the broad number of Omicron cases.

And absenteeism applies not just to healthcare workers, but our own employees working in factories and our distribution centers, our suppliers, it was broad-based. And so that absenteeism, plus the COVID cases suppressing elective cases in hospitals, that peaked the second half of January and into the first half of February.

And trends are now favorable, as we highlighted – indicated with our Q4 guidance. And we think procedure volumes will improve throughout March and April and back to pre-COVID levels by the end of our fiscal Q4.

However, you still have these chronic staffing shortages that will be – from what we are hearing from hospital administrators persist, into FY ‘23, but how – into 2023, sorry.

But they are – they will be mitigated by these traveling or temporary staff, where the hospitals are just paying more for these employees and technologies like remote monitoring and telehealth. And so we think that those mitigants will allow them to get back to the normal levels.

But it will maybe limit them from going 110% or 120% of pre-COVID levels like we saw in prior waves, prior to Delta and Omicron. So, that’s how we are seeing it, and it does imply a big improvement here in Q4. But we don’t see that hospitals have a capacity to kind of handle 110%, 120% kind of levels like we have seen in other waves.

So, I hope that answers that question. And then maybe on the China piece, I will turn that over to Karen..

Yes. Thanks, Geoff. On China, it was a bit flat in Q3 and we did see some regional tenders happening or beginning to happen in the trauma space. And as we see those tenders happening, the channel slows down their buying. So, that just happens in advance.

But just on VBP in general in China, we do expect the government to focus on the top 10 medical device products by public insurance spending. And as you know, we have been through stents and other industry players have gone through large joints. I mentioned, we are now seeing this regional trauma tender.

And we see two more potential national tenders on that list where we have exposure, and that would be in spine and surgical stapling. And obviously, there is a lot of uncertainty around these tenders, including timing.

But just so you know, if you look at our spine and stapling business in China, our gross exposure is somewhere between 1% to 1.5% of the total company revenue.

And based on what we experienced with stents, there should be offsets to that ultimate – to the ultimate number, so that the net would be less than the gross that I mentioned, because we have got pull-through of products and we will obviously be working those. We are anticipating at least one of those tenders to happen in FY ‘23.

And these are among the things that put pressure on the plus side of our long-term 5% plus goal for next year. So, I hope that’s helpful..

Thank you so much Karen..

Thanks Larry. Next question Win..

The next question comes from Joanne Wuensch at Citi..

Good morning.

Can you hear me okay?.

Yes, sure, Joanne.

How are you doing?.

I am doing okay. Thank you for taking my question.

I want to just build off of Karen’s last comments on the plus side of the 5%, somewhat for next year, but even the year after that, what needs to happen in order for you to get there? And specifically, I do have a number of investors who think or say they can’t get the plus side without a diabetes turnaround..

Well, I think what I like about our position right now is the breadth of the – the strength of the current portfolio and the strength and breadth of the pipeline. And we have several drivers. There is a lot of focus on – obviously, on Hugo, and we talked about that and we are feeling good there.

And certainly, by that time, we will work through some of these manufacturing and supply chain issues. And we are feeling really good about the quality of what we have here and the impact that Hugo is going to have. We will get the Ardian data readout as well. And I will come back – we talked about diabetes.

But beyond that, you have got things like – and I will just highlight a few, and I will start in cardiovascular, you got our EV-ICD coming, we see that market to be $2 billion to $3 billion. And then our Cardiac Ablation Solutions business there for Afib, we have got PFA. Of course, our DiamondTemp rollout is – will peak, and we have got PFA coming.

In MedSurg, beyond Hugo, SI is hitting a nice part of its product cycle here. There is a number of products that will have an impact coming in SI. And then our neuroscience portfolio just across the board is well positioned.

You heard in the commentary about neuromodulation with DPN in pain, ECAPs in pain, and that’s strength-on-strength because our DTM is doing well there. You got DBS with the sensing and the closed loop. Pelvic health, that market continues to be a stronger growth market and we have got a great product line up there. ENT will be adding Intersect.

And I really believe our spine business is poised with the broad base of enabling technology and just where that market is going. It definitely favors us. And then you heard today that neurovascular is back to gaining share. We have – over the years, we have relied on that. So, it’s a broad base of technology.

And I think with the new operating model, I expect it to keep refilling that pipeline up, that’s the focus. So, that’s what I would say. We feel good about – as Karen said, there is more puts and takes next year than normal for sure, and she has gone through that, I think in good detail.

But the – we are committed to the long-term plan, and it starts with this top line growth. And based on the broad nature of it, we feel good. And getting back to Diabetes, remember, we do have the 780G with the Guardian 4 sensor. We will have a new sensor beyond that in that timeframe with Simplera.

And that Simplera sensor could also be paired with our pen from companion and creating a whole new vector of growth for our diabetes business there with smart pens paired with our sensor. So, there is a number of drivers there. And you take it all, it doesn’t all need to happen to get to that 5% plus once you get past FY ‘23..

And Joanne, I just want to emphasize from the – from my seat, that we are really confident in that 5% plus over the long-term. And it is because it’s not dependent on any one thing, but it’s the strength of the pipeline that Geoff mentioned..

Excellent. Thank you so much..

Thanks, Joanne. Next question Win..

The next question comes from the line of Danielle Antalffy from SVB Leerink..

Hi Danielle..

I am so sorry.

Can you guys hear me okay?.

Yes, we can hear you. Just fine..

Okay. Great. Thank you so much. And appreciate all the commentary you guys provided as we look out over the next fiscal year. Just a quick question as you think about the ramp in major new product launches. So, you have talked about Hugo a little bit here, but there is obviously also RBN.

And just to follow-up on Joanne’s question, I guess as we think about fiscal ‘24 and beyond, so beyond the next fiscal year, how we should be thinking about that ramp? I know we are waiting for the data. But has anything changed as far as thinking about contribution for some of these major new product launches? Thank you so much..

Well, on the Ardian question, maybe I will pull in Sean Salmon here to provide an update on Ardian..

So Geoff, I think the data readout on Ardian, we are expecting now in that kind of late fall, early winter timeframe of this calendar year. But there may be a milestone in between now and then and give you more confidence. We have the 3-year data from the pilot trial ON MED’s being presented at ACC this year.

And why that’s important is that will be the first time we have had randomized data with long-term follow-up. So, the question around how long does the effect last? It doesn’t wear out. That’s going to be really important for payers. It’s an important inflection point. But we remain very confident.

All the body of evidence that we had for Ardian has continued to be very consistent, and we are making preparations to really go after a blockbuster launch here..

Good. And another one that we have mentioned a little bit in the commentary, Danielle, that maybe I will have Brett Wall comment on is two things in pain. Our pain business is already well positioned with our DTM.

But the diabetic peripheral neuropathy and the ECAPs submission, do you want to comment on those two things, Brett, because I think they are pretty meaningful..

Yes, sure. Danielle, these two things are pretty meaningful. We received the diabetic peripheral neuropathy approval about 2.5 years before we anticipated that. We think that’s a market that, as Geoff said in the commentary, is going to grow to $300 million pretty quickly. We are well positioned with that.

And the data there that we submitted is very strong data, and it’s reflective of the other data that has been presented in that same field. So, we have every right to win there, and we will be investing and moving accordingly. In addition, we submitted late last year our ECAPs filing. And ECAPs is a closed-loop algorithm that will be utilized in SCS.

And we are back to gaining share, really across the neuromodulation portfolio, but in SCS in particular with DTM and now with the embodiment of our stimulation programs with the sensing capability to close the loop and allow for really more effective therapy there.

So, the entirety of this portfolio is set up as the markets recover and as procedures recover, as we wind down Omicron for share gain and growth across the field with more effective therapies in this entire area..

Yes. And so just last comment on that. I mean look, obviously, they are both great opportunities. But the other piece that I really like about them is just how we did this, right. These – in both cases, you had smaller and in one case with ECAP start-up, smaller focused companies that signaled the innovation here.

Historically, we haven’t moved that fast and now we are moving at a much faster pace. And I just love the way we put these focus teams on there, gave them this challenge in both of these instances to move fast, don’t sacrifice quality but move fast.

And this is the type of thing that we want to see – we are starting to see across the portfolio with the new operating model, with the leaders we have in place, with some of the new leaders we brought in from outside the company.

And like I said earlier, also now beyond innovation, moving on to really improving our capabilities in our end-to-end supply chain to make sure that it’s reliable and it sets us up from a cost position as well. So, like where the company is headed, like those two examples in particular..

Thank you so much..

Thanks, Danielle. And I apologize, we are not going to be able to get to all the analysts today, but we do have time for one more question.

Can we take that Win?.

Our final question comes from Rick Wise at Stifel. Go ahead Rick..

Thanks Win. Good morning Geoff. Hi Karen.

Maybe just given your commentary about and the appreciation for your stepped-up R&D spending and your comment about using a portion of cash flow for continuing M&A sort of in a sense an extension of R&D, can you talk a little more, just give us your latest thinking on how your reflections on your targets? Are there a lot of opportunities? Are there a lot of opportunities to increase your minority investments? Where are you – what are you prioritizing for the calendar year and the next several years? What are you targeting? Just any updates would be very welcome.

Thank you..

Sure. Rick, great to hear from you. Thanks for that question. I will answer it a couple of ways. One, this is separate. These tuck-in acquisitions and venture investing, that’s separate from the broader portfolio comments I made earlier. This is what we view part of our everyday business here is doing tuck-ins. And so a couple of things I would say.

One, we have stepped up our venture investing. We separated our venture team maybe 2 years ago from our M&A team to have more focus. We have separate operating mechanisms with these – with this team, that Karen, myself and several others from the Executive Committee participate in. And so we have stepped up those investments.

And a lot of those investments, some of them are just debt or equity, but some of them are more structured investments to give us opportunities down the line. So, that is significantly up. And then on the acquisition space, I was hoping, like I said in prior calls, that during COVID, evaluations would go down a bit and present opportunities.

That didn’t happen initially, but valuations have come down a bit. And our pipeline is fuller than it has been over the last 2 years. You see the Intersect deal.

That Intersect deal for ENT that we announced and the Affera deal for our Ablation Solutions business, those are the type of like acquisitions in that billion – multibillion dollar range that have – in the case of Intersect ENT, will have an immediate impact because they have got meaningful revenue. The Affera deal, it will take a little bit longer.

It’s still earlier in development, but hugely impactful. What I like about that deal is how it repositions our – really strengthens our ablation business there by providing the MapNav and complements our PFA offerings. So, we are seeing things across the board, if you will.

Particularly, I would say, a lot of interesting things in neuroscience, a lot of interesting things in the cardiology space as well. So, that’s how I would answer that question..

Thank you very much..

Thanks, Rick. Geoff, please go ahead with your closing remarks..

Okay. Alright. Thanks, Ryan. Okay. Look, thanks, everybody, for the great questions. And we appreciate – certainly appreciate your support and your continued interest in Medtronic. And look, we obviously – Karen outlaid – outlined some of the puts and takes that we have that we are working through.

But we also have like some extraordinary opportunities in the marketplace and you combine that with the changes that we have made in the company and continue to make that I think are having a meaningful impact, I am confident in our ability to work – move past these – work through these challenges and move past these challenges and deliver on these opportunities and deliver on that plan, that long range plan that we have outlined.

And we are steadfast in our commitment to deliver durable and higher growth. So look, we hope you join us for our Q4 earnings webcast, which we anticipate holding on May 26, where we will update you on how we finish the fiscal year and then even a more detailed look ahead at fiscal ‘23. So with that, thanks for tuning in today.

Please stay healthy and safe, and have a great rest of your day..